Healthcare Professionals
Please log in for special information and services
New here?
sign up for personal account
Anne Worrallo-Hickman Country Manager UK

"I joined AOP Orphan Ltd in 2016 bringing 25 years experience in senior management within the Healthcare Industry. AOP Orphan has a long history of developing medicines for rare disease and delivering significant improvements to the health of patients! I am committed to introducing that expertise into the UK!"

Facts & Figures

AOP Orphan is fully dedicated to pharmaceutical and clinical development as well as commercialisation of drugs for more than 20 years already.

Our motivation at AOP Orphan is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the UK health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases. 

UK occupies a special position among many countries where AOP Orphan is represented. In this market, the company began its development in 2012. AOP Orphan UK is a team in the Marketing & Sales for all three therapeutic divisions.

 

3.5m
people
PATIENTS WITH RARE DISEASES IN UK
In Europe those diseases that occur in less than 5 per 10,000 residents are defined as rare diseases. Those are 3.5 million people in UK, and a single rare disease may affect up to about 30,000 people.
available treatments
In UK AOP Orphan provides ten products and innovative treatments.
10
products
3
therapeutic areas
THREE THERAPEUTIC AREAS
AOP Orphan in UK covers three therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders.